AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38466266 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intervention (9 monthly video lessons and 1 week of self-monitoring per month)
Number of subjects: 540
Study 38466266 — intervention group
Group type: EXPERIMENTAL
Intervention: Refresher intervention (an introductory session and two 4-week periods of lessons and self-monitoring at 7 and 10 months)
Number of subjects: 540
Study 38466266 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (monthly online newsletters)
Number of subjects: 540
Study 38466266 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial 3-month intervention (Rx Weight Loss program)
Number of subjects: 540
Study 38466274 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (n=1541)
Number of subjects: 3000
Study 38466274 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (n=1459)
Number of subjects: 3000
Study 38466274 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 3000
Study 38466274 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 3000
Study 38466302 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS system with tailored, evidence-based recommendations
Number of subjects: 2026
Study 38466302 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2026
Study 38466302 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS system
Number of subjects: 2026
Study 38466872 — intervention group
Group type: EXPERIMENTAL
Intervention: VR neuroscience-based therapy (VRNT)
Number of subjects: 31
Study 38466872 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waitlist control)
Number of subjects: 31
Study 38466972 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral CBD therapy (2.5 mg per kg per day for 16 days)
Number of subjects: 53
Study 38466972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 38466984 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged nightly fasting for 4 months
Number of subjects: 6
Study 38466984 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged nightly fasting
Number of subjects: 6
Study 38467003 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D supplementation (1000 mg of calcium carbonate with 400 IU of vitamin D)
Number of subjects: 36282
Study 38467003 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D supplementation
Number of subjects: 36282
Study 38467031 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive transfer of donor B cells (0.5 × 10^6 to 4.0 × 10^6 B cells per kg body weight)
Number of subjects: 15
Study 38467031 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive transfer of donor B cells
Number of subjects: 15
Study 38467131 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy (400 mg oral once daily after a 5-week ramp-up)
Number of subjects: 258
Study 38467273 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Voices Video
Number of subjects: 1606
Study 38467273 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Reminders
Number of subjects: 1606
Study 38467273 — intervention group
Group type: EXPERIMENTAL
Intervention: Both video and reminders
Number of subjects: 1606
Study 38467273 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1606
Study 38467273 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes via survey
Number of subjects: 1606
Study 38467379 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy (SABR)
Number of subjects: 40
Study 38467383 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback treatment (n=19)
Number of subjects: 42
Study 38467383 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n=23)
Number of subjects: 42
Study 38467604 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoimmunotherapy with camrelizumab (200 mg), nab-paclitaxel (260 mg/m2), and cisplatin (dosage not specified)
Number of subjects: 0
Study 38467639 — intervention group
Group type: EXPERIMENTAL
Intervention: Bavituximab plus pembrolizumab
Number of subjects: 28
Study 38467646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine
Number of subjects: 1551
Study 38467646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1551
Study 38467716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochleural Alternating Acoustic Beam Therapy (CAABT)
Number of subjects: 60
Study 38467716 — intervention group
Group type: COMPARATOR
Intervention: Traditional Sound Therapy (TST)
Number of subjects: 60
Study 38467760 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP ratio
Number of subjects: 2917
Study 38467760 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP, hsCRP, and neutrophil-to-lymphocyte ratio
Number of subjects: 2917
Study 38467864 — intervention group
Group type: EXPERIMENTAL
Intervention: Canon CR2 AF AF camera
Number of subjects: 900
Study 38467864 — intervention group
Group type: EXPERIMENTAL
Intervention: Topcon TRC-NW400
Number of subjects: 900
Study 38467864 — intervention group
Group type: EXPERIMENTAL
Intervention: Optomed Aurora
Number of subjects: 900
Study 38467912 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (15 mg once daily)
Number of subjects: 392
Study 38467918 — intervention group
Group type: EXPERIMENTAL
Intervention: CareAvenue (digital intervention with eight videos addressing unmet social needs)
Number of subjects: 600
Study 38467945 — intervention group
Group type: COMPARATOR
Intervention: Immediate implant placement (IIP) without grafting
Number of subjects: 39
Study 38467945 — intervention group
Group type: COMPARATOR
Intervention: Immediate implant placement (IIP) with autogenous tooth bone graft (ATBG)
Number of subjects: 39
Study 38467945 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (SMV) gel mixed with ATBG around IIP
Number of subjects: 39
Study 38468231 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma levels of NRP-1
Number of subjects: 65
Study 38468231 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma levels of PlGF
Number of subjects: 65
Study 38468231 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma levels of both NRP-1 and PlGF
Number of subjects: 65
Study 38468231 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline NRP-1 level
Number of subjects: 65
Study 38468231 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline VEGF receptor-2 level
Number of subjects: 65
Study 38468241 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 72
Study 38468241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 38468259 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µM quercetin for three days
Number of subjects: 11
Study 38468259 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg/day quercetin for 6 months
Number of subjects: 11
Study 38468259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 38468266 — intervention group
Group type: EXPERIMENTAL
Intervention: Core implementation strategies (IS)
Number of subjects: 12
Study 38468266 — intervention group
Group type: COMPARATOR
Intervention: Core+ implementation strategies (IS)
Number of subjects: 12
Study 38468293 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy (EXP)
Number of subjects: 380
Study 38468293 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 380
Study 38468320 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel 4-month treatment regimens
Number of subjects: 0
Study 38468320 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 38468321 — intervention group
Group type: EXPERIMENTAL
Intervention: Early assessment Team (EaT)
Number of subjects: 588
Study 38468321 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 588
Study 38468338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency plasma donors (HFPDs) donating 650 mL of plasma 3 times every 2 weeks
Number of subjects: 120
Study 38468338 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular-frequency plasma donors (RFPDs) donating 650 mL of plasma 1 time every 2 weeks
Number of subjects: 120
Study 38468338 — intervention group
Group type: COMPARATOR
Intervention: Whole blood donors (control group)
Number of subjects: 120
Study 38468418 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia (CBT-I)
Number of subjects: 150
Study 38468440 — intervention group
Group type: COMPARATOR
Intervention: >0% weight gain
Number of subjects: 1030
Study 38468440 — intervention group
Group type: COMPARATOR
Intervention: >2.5% weight gain
Number of subjects: 1030
Study 38468440 — intervention group
Group type: COMPARATOR
Intervention: >5.0% weight gain
Number of subjects: 1030
Study 38468620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertile 3 (≥ 7.51 h) sleep duration
Number of subjects: 91
Study 38468620 — intervention group
Group type: COMPARATOR
Intervention: Tertile 1 (≤ 6.5 h) sleep duration
Number of subjects: 91
Study 38468620 — intervention group
Group type: COMPARATOR
Intervention: Tertile 2 (6.51-7.50 h) sleep duration
Number of subjects: 91
Study 38469035 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic minority women (DMW)
Number of subjects: 1437
Study 38469035 — intervention group
Group type: COMPARATOR
Intervention: Other diabetic patients
Number of subjects: 1437
Study 38469548 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole
Number of subjects: 12
Study 38469583 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with digital patient support (SC + DPS)
Number of subjects: 100
Study 38469583 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 100
Study 38469654 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with significant primary MR
Number of subjects: 111
Study 38469686 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate curative therapy (radiotherapy or prostatectomy)
Number of subjects: 980
Study 38469686 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (endocrine therapy or observation)
Number of subjects: 980
Study 38469689 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-enabled quantitative plaque analysis
Number of subjects: 4430
Study 38469689 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 4430
Study 38469809 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 0
Study 38469809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38470299 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 138
Study 38470404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus lenvatinib
Number of subjects: 0
Study 38470404 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (paclitaxel or doxorubicin)
Number of subjects: 0
Study 38470420 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg subcutaneously for 6 months
Number of subjects: 55
Study 38470420 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment of cardiovascular risk factors (control group) for 6 months
Number of subjects: 55
Study 38470426 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in light physical activity
Number of subjects: 235
Study 38470426 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance in the 4-m gait test
Number of subjects: 235
Study 38470426 — intervention group
Group type: EXPERIMENTAL
Intervention: Score on the short version of the Mini-Nutritional Assessment
Number of subjects: 235
Study 38470426 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported fatigue
Number of subjects: 235
Study 38470426 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Nutritional Assessment score
Number of subjects: 235
Study 38470426 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in moderate physical activity
Number of subjects: 235
Study 38470426 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow gait speed
Number of subjects: 235
Study 38470444 — intervention group
Group type: EXPERIMENTAL
Intervention: Posoleucel
Number of subjects: 0
Study 38470444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38470447 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalpiciclib plus non-steroidal aromatase inhibitor (NSAI)
Number of subjects: 2
Study 38470447 — intervention group
Group type: COMPARATOR
Intervention: Abemaciclib plus non-steroidal aromatase inhibitor (NSAI)
Number of subjects: 2
Study 38470460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nthabi health promotion app used on smartphones or tablets for up to 6 weeks
Number of subjects: 172
Study 38470460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nthabi health promotion app
Number of subjects: 172
Study 38470468 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media intervention (4, 8, 16, and 32 exposures over 15 days)
Number of subjects: 1491
Study 38470468 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 exposures)
Number of subjects: 1491
Study 38470476 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC tool Easy-ICD
Number of subjects: 0
Study 38470476 — intervention group
Group type: COMPARATOR
Intervention: Manual coding processes
Number of subjects: 0
Study 38470512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 38470512 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 0
Study 38470867 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver contribution to self-care
Number of subjects: 510
Study 38470867 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-care
Number of subjects: 510
Study 38470985 — intervention group
Group type: EXPERIMENTAL
Intervention: LetibotulinumtoxinA
Number of subjects: 1272
Study 38470985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1272
Study 38471042 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical methods for limb salvage
Number of subjects: 345
Study 38471042 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-age group (≤10 years)
Number of subjects: 345
Study 38471042 — intervention group
Group type: EXPERIMENTAL
Intervention: High-age group (>10 years)
Number of subjects: 345
Study 38471042 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular prosthesis
Number of subjects: 345
Study 38471042 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 345
Study 38471042 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 345
Study 38471042 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of local relapse rate (LRR)
Number of subjects: 345
Study 38471042 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of metastasis
Number of subjects: 345
Study 38471042 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthesis-related complications
Number of subjects: 345
Study 38471063 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-party, single-donor fecal microbiota transplantation (FMT) administered in combination with systemic corticosteroids. Induction dose: 15 capsules per day for 2 consecutive days, followed by 3 weekly maintenance doses of 15 capsules each.
Number of subjects: 10
Study 38471061 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Number of subjects: 356
Study 38471061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 38471091 — intervention group
Group type: EXPERIMENTAL
Intervention: Care coordination programs (CCPs) for HIV care
Number of subjects: 57
Study 38471091 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine provision of emotional support by providers
Number of subjects: 57
Study 38471091 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and referrals to psychiatric and/or psychological care
Number of subjects: 57
Study 38471091 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for providers
Number of subjects: 57
Study 38471091 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation of emotional support provision
Number of subjects: 57
Study 38471293 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration (≤6 h per night)
Number of subjects: 2504
Study 38471293 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep duration (>6 and ≤8 h)
Number of subjects: 2504
Study 38471293 — intervention group
Group type: EXPERIMENTAL
Intervention: Long sleep duration (>8 h)
Number of subjects: 2504
Study 38471293 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration (≤6 h per night) in old age
Number of subjects: 2504
Study 38471293 — intervention group
Group type: EXPERIMENTAL
Intervention: Long sleep duration (>8 h) in old age
Number of subjects: 2504
Study 38471311 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth-based relaxation program (8 weeks, including progressive muscle relaxation, guided imagery, and mindfulness)
Number of subjects: 50
Study 38471311 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 50
Study 38471416 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab Q4W + cisplatin + etoposide + radiotherapy (Arm 1)
Number of subjects: 64
Study 38471416 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab Q4W + carboplatin + paclitaxel + radiotherapy (Arm 2)
Number of subjects: 64
Study 38471416 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab Q4W + carboplatin or cisplatin + pemetrexed + radiotherapy (Arm 3)
Number of subjects: 64
Study 38471416 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with cCRT
Number of subjects: 64
Study 38471508 — intervention group
Group type: EXPERIMENTAL
Intervention: i.p. nivolumab monotherapy
Number of subjects: 23
Study 38471508 — intervention group
Group type: EXPERIMENTAL
Intervention: i.p. nivolumab every 2 weeks and i.p. ipilimumab every 6 weeks
Number of subjects: 23
Study 38471641 — intervention group
Group type: EXPERIMENTAL
Intervention: Be Well Home Health Navigator Program
Number of subjects: 0
Study 38471641 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 38471681 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-processed diet (UPF)
Number of subjects: 55
Study 38471681 — intervention group
Group type: COMPARATOR
Intervention: Minimally processed diet (following UK dietary guidance)
Number of subjects: 55
Study 38471681 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month behavioural support programme aimed at reducing UPF intake
Number of subjects: 55
Study 38471711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 600 mg intravenously Q4W for up to 48 weeks
Number of subjects: 63
Study 38471711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 600 mg intravenously Q4W
Number of subjects: 63
Study 38471727 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC 0/1-h algorithm with hs-cTnT
Number of subjects: 1430
Study 38471727 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC 0/1-h algorithm with HEART score
Number of subjects: 1430
Study 38471727 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1430
Study 38471825 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 74
Study 38471825 — intervention group
Group type: COMPARATOR
Intervention: Suspension of Rilonacept
Number of subjects: 74
Study 38471990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mito-MES 20 mg daily for 14 days
Number of subjects: 80
Study 38471990 — intervention group
Group type: COMPARATOR
Intervention: No Mito-MES (control)
Number of subjects: 80
Study 38471990 — intervention group
Group type: EXPERIMENTAL
Intervention: Mito-MES
Number of subjects: 80
Study 38472049 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week abdominal and pelvic floor muscle exercise program during pregnancy
Number of subjects: 96
Study 38472049 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 96
Study 38472241 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase treatment
Number of subjects: 592
Study 38472381 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of absorbent pyjama pants (APP) after a 4-week run-in period.
Number of subjects: 0
Study 38472381 — intervention group
Group type: COMPARATOR
Intervention: Continuation of absorbent pyjama pants (APP) after a 4-week run-in period.
Number of subjects: 0
Study 38472528 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0
Study 38472611 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuterium metabolic imaging (DMI) of glucose and its downstream metabolites
Number of subjects: 6
Study 38472696 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg (single and multiple doses)
Number of subjects: 18
Study 38472696 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg (single dose)
Number of subjects: 18
Study 38472696 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 2 mg and Warfarin 25 mg (concomitant administration)
Number of subjects: 18
Study 38473239 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-96191, a novel CD33/CD16a/NKG2D immune-modulating TriNKET
Number of subjects: 0
Study 38473248 — intervention group
Group type: EXPERIMENTAL
Intervention: Besifovir (BSV) treatment for up to 8 years
Number of subjects: 188
Study 38473278 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 0
Study 38473278 — intervention group
Group type: COMPARATOR
Intervention: Control group with impaired renal function (not specified)
Number of subjects: 0
Study 38473704 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR/Cas9-based genome editing
Number of subjects: 0
Study 38473704 — intervention group
Group type: COMPARATOR
Intervention: Lentivirus (LV) and Adeno-associated virus (AAV) based gene therapy
Number of subjects: 0
Study 38475751 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-breath (TB) method
Number of subjects: 118
Study 38475751 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 118
Study 38475757 — intervention group
Group type: EXPERIMENTAL
Intervention: No menthol restriction (menthol cigarette and menthol flavored e-cigarette)
Number of subjects: 150